METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors.

Date publication

janvier 2024

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal , Pr ENTZ-WERLE Natacha

Tous les auteurs :
André N, Deley MCL, Léguillette C, Probst A, Willems L, Travers R, Aerts I, Faure-Conter C, Revond-Riviere G, Min V, Geoerger B, Chastagner P, Entz-Werlé N, Leblond P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38199147

Résumé

This multicenter Phase I study (NCT03585465) evaluated nivolumab in combination with 3 metronomic chemotherapy (MC) regimens in children with refractory/relapsing solid tumors.

Mots clés

Immune checkpoint inhibitors, Immunotherapy, Metronomic chemotherapy, Pediatric cancer

Référence

Eur J Cancer. 2024 01 6;198:113525